Skip to main content

Table 1 Demographic and clinical characteristics of study cohort in MIMIC III

From: Early prediction of ventilator-associated pneumonia in critical care patients: a machine learning model

 

Overall

(n = 10,431)

VAP group

(n = 212)

Non-VAP group

(n = 10,219)

p value

Age(years), median(IQR)

66.3 (53.1–76.0)

66.3 (52.1–77.8)

66.3 (53.1–76.0)

0.387

Gender, n(%)

   

0.107

 Male

5937 (56.9)

109 (51.4)

5828 (57.0)

 

 Female

4494 (43.1)

103 (48.6)

4391 (43.0)

 

Admission source, n(%)

   

 < 0.001

 MICU

4089 (39.2)

154 (72.6)

3935 (38.5)

 

 Other ICU

6342 (60.8)

58 (27.4)

6284 (61.5)

 

Admission type, n(%)

   

 < 0.001

 Emergency

9504 (91.1)

211 (99.5)

9293 (90.9)

 

 Elective

927 (8.9)

1 (0.5)

926 (9.1)

 

Reintubation, n(%)

3294 (31.6%)

65 (30.7%)

3229 (30.6%)

0.823

Pre-existing Diseases, n(%)

    

 COPD

101 (1.0%)

2 (0.9%)

99 (1.0)

1.0

 Diabetes

2698 (25.9)

60 (28.3)

2638 (25.8)

0.428

 Hypertension

4943 (47.4)

80 (37.7)

4863 (47.6)

0.004

 Solid tumor

313 (3.0)

8 (3.8)

305 (3.0)

0.537

 Metastatic tumor

418 (4.0)

5 (2.4)

413 (4.0)

0.286

 Renal failure

1721 (16.5)

26 (12.3)

1695 (16.6)

0.111

 Liver failure

1653 (15.9)

22 (10.4)

1631 (16.0)

0.028

PaO2/FiO2, median(IQR)

240.0 (178.5–315.4)

194.17 (150.0–256.5)

241.0 (179.4–316.7)

 < 0.001

WBC(K/uL), median(IQR)

12.8 (9.2–17.7)

13.2 (9.8–18.0)

12.8 (9.2–17.7)

0.121

Body temperature(℃), median(IQR)

37.8 (37.3–38.4)

37.9 (37.3–38.6)

37.8 (37.3–38.4)

0.255

APACHE III score, median(IQR)

50.0 (37.0–66.0)

53.0 (40.75–64.0)

50.0 (37.0–66.0)

0.031

 HR

5.0 (0.0–7.0)

5.0 (0.0–7.0)

5.0 (0.0–7.0)

0.028

 MAP

15.0 (7.0–15.0)

15.0 (7.0–15.0)

15.0 (7.0–15.0)

0.197

 Temperature

0.0 (0.0–2.0)

0.0 (0.0–2.0)

0.0 (0.0–2.0)

 < 0.001

 RR

6.0 (0.0–6.0)

6.0 (0.0–9.0)

6.0 (0.0–6.0)

0.001

 A-aDO2/PaO2

0.0 (0.0–0.0)

0.0 (0.0–0.0)

0.0 (0.0–0.0)

 < 0.001

 Hematocrit

3.0 (3.0–3.0)

3.0 (3.0–3.0)

3.0 (3.0–3.0)

0.269

 WBC

0.0 (0.0–1.0)

0.0 (0.0–1.0)

0.0 (0.0–1.0)

0.083

 Creatinine

0.0 (0.0–7.0)

0.0 (0.0–7.0)

0.0 (0.0–7.0)

0.484

 UO

5.0 (0.0–7.0)

5.0 (0.0–7.0)

5.0 (0.0–7.0)

0.013

 BUN

7.0 (2.0–11.0)

7.0 (2.0–11.0)

7.0 (2.0–11.0)

0.094

 Sodium

0.0 (0.0–2.0)

0.0 (0.0–2.0)

0.0 (0.0–2.0)

0.016

 ALB

0.0 (0.0–6.0)

0.0 (0.0–6.0)

0.0 (0.0–6.0)

0.087

 Bilirubin

0.0 (0.0–0.0)

0.0 (0.0–0.0)

0.0 (0.0–0.0)

0.008

 Glucose

0.0 (0.0–3.0)

3.0 (0.0–3.0)

0.0 (0.0–3.0)

0.017

 Acid–base

3.0 (1.0–6.0)

3.0 (1.0–5.0)

3.0 (1.0–6.0)

0.077

 GCS

0.0 (0.0–0.0)

0.0 (0.0–0.0)

0.0 (0.0–0.0)

0.017

SOFA score, median(IQR)

6.0 (4.0–9.0)

6.0 (4.0–8.0)

6.0 (4.0–9.0)

0.034

 Respiration

3.0 (0.0–3.0)

3.0 (2.0–3.0)

3.0 (0.0–3.0)

0.014

 Coagulation

0.0 (0.0–1.0)

0.0 (0.0–1.0)

0.0 (0.0–1.0)

 < 0.001

 Liver

0.0 (0.0–1.0)

0.0 (0.0–0.0)

0.0 (0.0–1.0)

0.004

 Cardiovascular

1.0 (1.0–3.0)

1.0 (1.0–3.0)

1.0 (1.0–3.0)

0.022

 CNS

0.0 (0.0–1.0)

0.0 (0.0–0.0)

0.0 (0.0–1.0)

0.008

 Renal

1.0 (0.0–2.0)

1.0 (0.0–2.0)

1.0 (0.0–2.0)

0.471

Coma adm, n(%)

6 (0.1%)

0 (0.0%)

6 (0.1%)

1.0

Aspiration adm, n(%)

32 (0.3%)

4 (1.9%)

28 (0.3%)

0.004

Sepsis adm, n(%)

548 (5.3%)

10 (4.7%)

538 (5.3%)

0.876

Bacteremia adm, n(%)

11 (0.1%)

0 (0.0%)

11 (0.1%)

1.0

Trauma adm, n(%)

202 (1.9%)

0 (0.0%)

202 (2.0%)

0.037

Polytrauma adm, n(%)

45 (0.4%)

0 (0.0%)

45 (0.4%)

1.0

Fracture adm, n(%)

27 (0.3%)

0 (0.0%)

27 (0.3%)

1.0

Pneumothorax adm, n(%)

19 (0.2%)

0 (0.0%)

19 (0.2%)

1.0

  1. MICU medical intensive care unit, APACHE III Acute Physiology and Chronic Health Evaluation III, PaO2/FiO2 the partial pressure of arterial oxygen/ fraction of inspired oxygen, WBC white blood cell count, HR heart rate, MAP mean arterial pressure, RR respiratory rate, A-aDO2/PaO2 pulmonary alveolus-arterial difference of oxygen pressure/ partial pressure of oxygen, UO urine output, BUN blood urea nitrogen, ALB albumin, GCS Glasgow Coma Scale, SOFA sequential organ failure assessment, CNS central nervous system, COPD chronic obstructive pulmonary disease, adm admission